BioTech

CAR-T, money talk, and the cancer treatment ‘sandwich’


You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for the last day here.

ASCO is more than half done. There is free coffee on the exhibit floor. One booth barista said their team had made 1,400 espressos in a day. Everyone’s perspective is alternating between two verses from Smashing Pumpkins, who are, lest you forget, a Chicago band. “Today is the greatest day I’ve ever known.” Also: “I’ll burn my eyes out before I get out.”

What if sometimes cancer doctors could give less medicine?

Are cancer drugs more likely to be cures? Or could they instead turn cancer into a chronic disease, in which medicines keep tumors in check but patients have to deal with their side effects, both physical and financial, for the rest of their lives.

STAT+ Exclusive Story

STAT+





This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe





Source

Related Articles

Back to top button